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Abstract 
Background: Molecular targeting remains to be a promising approach in oncology. Overexpression of G 
protein-coupled receptors (GPCRs) in human cancer is offering a powerful opportunity for tumor-selective 
imaging and treatment employing nuclear medicine. We utilized novel chemerin-based peptide conjugates for 
chemokine-like receptor 1 (CMKLR1) targeting in a breast cancer xenograft model.  
Methods: By conjugation with the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 
we obtained a family of five highly specific, high-affinity tracers for hybrid positron emission 
tomography/magnetic resonance (PET/MR) imaging. A xenograft model with target-positive DU4475 and 
negative A549 tumors in immunodeficient nude mice enabled CMKLR1-specific imaging in vivo. We acquired 
small animal PET/MR images, assessed biodistribution by ex vivo measurements and investigated the tracer 
specificity by blocking experiments. 
Results: Five CMKLR1-targeting peptide tracers demonstrated high biological activity and affinity in vitro with 
EC50 and IC50 values below 2 nM. Our target-positive (DU4475) and target-negative (A549) xenograft model 
could be validated by ex vivo analysis of CMKLR1 expression and binding. After preliminary PET imaging, the 
three most promising tracers [68Ga]Ga-DOTA-AHX-CG34, [68Ga]Ga-DOTA-KCap-CG34 and 
[68Ga]Ga-DOTA-ADX-CG34 with best tumor uptake were further analyzed. Hybrid PET/MR imaging along 
with concomitant biodistribution studies revealed distinct CMKLR1-specific uptake (5.1% IA/g, 3.3% IA/g and 
6.2% IA/g 1 h post-injection) of our targeted tracers in DU4475 tumor tissue. In addition, tumor uptake was 
blocked by excess of unlabeled peptide (6.4-fold, 5.5-fold and 3.4-fold 1 h post-injection), further confirming 
CMKLR1 specificity. Out of five tracers, we identified these three tracers with moderate, balanced 
hydrophilicity to be the most potent in receptor-mediated tumor targeting.  
Conclusion: We demonstrated the applicability of 68Ga-labeled peptide tracers by visualizing 
CMKLR1-positive breast cancer xenografts in PET/MR imaging, paving the way for developing them into 
theranostics for tumor treatment. 
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Introduction 
Molecular targeting remains to be one of the 
most promising approaches in cancer diagnosis and 
therapy. Targeted tracers in combination with highly 
sensitive positron emission tomography (PET) may 
facilitate early tumor recognition and staging as well 
as therapeutic stratification and response monitoring. 
While the most widely used PET tracer 









detection by glucose metabolic imaging and hence 
also visualizes non-neoplastic cells and tissues, 
tumor-specific targeting is aiming to provide more 
sensitive and precise imaging results with less 
non-specific background [1]. Preferred molecular 
targets are considered to localize at the cell surface or 
within the extracellular matrix (ECM), as tracers can 
reach them without crossing the cell membrane [2-4]. 
With either high overexpression or even exclusive 
target expression in tumor cells, appropriately 
targeted tracers may lead to improved 
tumor-to-background ratios and thus higher 
diagnostic sensitivity and specificity.  
G protein-coupled receptors (GPCRs) have 
emerged as molecular targets in the field of cancer 
care [5, 6]. Thus, upregulated receptor expression in 
cancer cells can be utilized for tracer-based tumor 
imaging, for pharmacological intervention through 
GPCR signaling modification and for peptide receptor 
radionuclide therapy (PRRT). Unlike antibodies, 
small-sized receptor ligands such as peptides have a 
number of advantages regarding their in vivo 
circulation, biodistribution, tumor penetration and 
low immunogenic potential [7-10].  
Chemokine-like receptor 1 (CMKLR1), a G 
protein-coupled receptor, and its ligand chemerin are 
known to be involved in inflammation, adipogenesis 
and glucose metabolism [11, 12]. CMKLR1 couples via 
the Gi/o family of G proteins and in cells expressing 
CMKLR1, chemerin inhibits production of cyclic AMP 
and promotes phospholipase C activation, IP3 release, 
calcium mobilization and activation of PI3K and 
MAPK pathways [13]. A nonameric peptide from the 
carboxyterminus of chemerin (chemerin-9) has been 
demonstrated to have equally high affinity for 
CMKLR1 and full agonistic activity [14]. 
Dysregulation of the receptor-ligand system has been 
linked to several pathologies such as metabolic 
syndrome and cardiovascular diseases [15, 16]. Apart 
from a study demonstrating recruitment of immune 
cells and hence an antitumor response in melanoma, 
the role of the chemoattractant chemerin and its 
receptors in cancer is largely unknown [17, 18]. 
Increased CMKLR1 expression, chemerin-mediated 
tumor cell migration and invasion in esophageal 
squamous cell carcinoma (ESCC) were found by 
Kumar et al. [19]. Likewise, CMKLR1 has been 
implicated in neuroblastoma proliferation [20], 
hepatocellular carcinoma metastasis [21] and 
migration/invasion of gastric cancer [22]. CMKLR1 
may therefore be a promising target for molecular 
imaging and targeted radionuclide therapy in 
overexpressing tumor entities. This study evaluated 
the potential of a family of novel CMKLR1 
peptide-DOTA tracers for PET/MR imaging in a 
breast cancer animal model. 
Material and Methods 
Peptides 
All peptides and DOTA-peptide conjugates were 
obtained from peptides&elephants (Hennigsdorf, 
Germany). They were analyzed by mass spectrometry 
to confirm the presence of the correct molecular mass. 
Peptides and peptide conjugates were used at a purity 
of greater than 95%. Analysis data for peptides and 
peptide conjugates have been deposited in an open 
data repository for public access: https://doi.org/ 
10.5281/zenodo.3334766 
Cell culture 
For in vitro analysis, HEK293a stably transfected 
with huCMKLR1 and Gα16 were used. For the in vivo 
mouse model, the human breast cancer cell line 
DU4475 with endogenous CMKLR1 expression and 
the target-negative human lung carcinoma cell line 
A549 were used. All cell lines were obtained from 
ATCC/LGC Standards (Wesel, Germany) and were 
cultured in RPMI1640 medium containing 10% fetal 
bovine serum (both from Biochrom, Berlin, Germany) 
and, in case of transfected cells, selection agents G418 
(Biochrom, Berlin, Germany) and zeocin (Invitrogen, 
Carlsbad, USA).  
Xenografts 
For in vivo experiments, at least 8-week-old 
female athymic NMRI-Foxn1nu /Foxn1nu mice (Janvier 
Labs, Saint-Berthevin, France) were used. Animal care 
followed institutional guidelines and all experiments 
were approved by local animal research authorities. 
For the generation of tumor xenografts, 5 x 106 cells of 
both DU4475 and A549 cells were inoculated 
subcutaneously into the right and left shoulder, 
respectively (1:1 phosphate-buffered saline 
[PBS]/Matrigel Basement Membrane Matrix High 
Concentration, Corning, Corning, USA). Part of the 
animals received SW13 lung cancer cells as a 
CMKLR1-negative control tumor. For the analysis of 
biodistribution, only data of DU4475 and A549 
xenograft tumors are used. Tumors were allowed to 
grow for two to four weeks (tumor volume > 100 
mm3) after cell inoculation.  
Immunofluorescence 
For immunofluorescent staining of tumor tissue, 
the frozen xenografts were embedded in Tissue-Tek 
O.C.T Compound (Sakura Finetek, Torrance, USA), 
trimmed by cryostat (12-18 µm) and transferred on 
glass slides (Superfrost, Thermo Fisher Scientific, 
Waltham, USA). Xenograft sections were fixed with 





1:1 methanol/acetone for two minutes and air-dried. 
After washing with PBS (Biochrom, Berlin, Germany), 
sections were blocked with 2% milk powder (blotting 
grade; Bio-Rad Laboratories, Hercules, USA) in PBS 
for 30 minutes. Sections were incubated with the 
primary anti-CMKLR1 antibody developed in our lab 
(#21-86; polyclonal from rabbit, immunogenic peptide 
sequence: SSWPTHSQMDPVGY; 3 µg/mL diluted in 
0.1% BSA in PBS) in a wet chamber over night at 4 °C. 
After washing, sections were incubated with the 
secondary antibody goat-anti-rabbit-Cy2 (Jackson 
ImmunoResearch, West Grove, USA; 7.5 µg/mL 
diluted in 0.1% BSA in PBS) for one hour. After 
washing with PBS, nuclei staining with 1 µg/mL 
4′,6-diamidino-2-phenylindole (DAPI) 
(Sigma-Aldrich, St. Louis, USA) in PBS followed. 
Finally, the cryosections were fixed with 96% ethanol 
for two minutes, embedded with Immu-Mount 
(Thermo Fisher Scientific, Waltham, USA) and 
analyzed with a confocal laser-scanning microscope 
(LSM510, Carl Zeiss, Jena, Germany). 
Determination of LogD7.4 values 
Compounds (3 µL of a 1 mM solution) were 
diluted into 300 µL PBS pH 7.4 or octanol and mixed. 
300 µL of the other phase was added, followed by 
vigorous mixing using a vortex shaker for one minute. 
The two phases were centrifuged (5 min, 10,000 x g). 
Following separation, 25 µL aliquots were removed 
for HPLC analysis. LogD7.4 was calculated by taking 
the logarithm of the ratio of the high-performance 
liquid chromatography (HPLC) peak area of each 
compound in octanol to the corresponding peak area 
in buffer. Consequently, logD7.4 values were based on 
analysis of both aqueous and octanol fractions. 
Calcium mobilization assay 
Optical ViewPlate 96-well microplates 
(PerkinElmer, Waltham, USA) were coated with 
poly-D-lysine (10 µg/mL, 50 µL/well) for 30 minutes 
at 37 °C, washed with PBS and air dried before 
seeding 40,000 HEK293a huCMKLR1 Gα16 cells per 
well. The next day, cells were starved with serum-free 
medium for 30 minutes and incubated with loading 
medium consisting of serum-free medium with 2.5 
mM probenicid (Sigma-Aldrich, St. Louis, USA) and 2 
µM Fluo-4 AM (Thermo Fisher Scientific, Waltham, 
USA). After a loading time of 45 minutes, cells were 
washed with 100 μL C1 buffer (130 mM NaCl, 5 mM 
KCl, 10 mM 4-(2-hydroxyethyl)-1-piperazinee-
thanesulfonic acid [HEPES], 2 mM CaCl2, 10 mM 
glucose) followed by 20 minutes of incubation in the 
dark. After another washing and incubation cycle, the 
cell plate was placed into the CellLux Calcium 
Imaging System (PerkinElmer, Waltham, USA) and 
the assay was performed automatically according to 
the following protocol. After a baseline measurement 
for 30 seconds, the ligands (prepared in C1 buffer with 
0.5% BSA in double concentration and pipetted in a 
U-bottom plate) were added on top of the cells and 
the fluorescence intensity was recorded for further 60 
seconds. Obtained raw data were analyzed using 
AssayPro (PerkinElmer, Waltham, USA). After spatial 
uniformity correction, maximum response values (F) 
were normalized to baseline values (F0) of each well 
using the following equation:  
response = ΔF/F0 = (F – F0)/F0.  
Iodination of chemerin-9 
Radioactive iodination of the nonapeptide 
chemerin-9 (Tyr-Phe-Pro-Gly-Glu-Phe-Ala-Phe-Ser, 
representing amino acids 149-157 of full-length 
chemerin) was performed by the chloramine T 
method [23]. For labeling, 10 nmol of chemerin-9 in 25 
μL iodination buffer (0.5 M sodium phosphate, pH 
7.4) were mixed with 1 mCi carrier-free Na[125I] 
(NEZ033L010MC, PerkinElmer, Waltham, USA) in an 
HPLC glass vial with microvolume insert. The 
reaction was started by adding 4 μL chloramine T (1 
mg/mL in water). After 20-30 seconds, 4 μL of sodium 
metabisulfite (2 mg/mL in water) were added to stop 
the iodination. HPLC purification was performed to 
separate unlabeled from labeled radioactive peptide 
on an Agilent ZORBAX 300 Extend-C18 column using 
a gradient from 20 to 50% acetonitrile (+0.1% TFA) 
against water (+0.1% TFA) for 20 minutes. First, 1-2 
μL of the reaction mixture were analyzed to 
determine the retention time of the radioactive 
peptide. This fraction was then collected during the 
main run, diluted with radioactive binding buffer to 
prevent radiolysis, aliquoted and stored at -20 °C. 
Competitive and saturation binding studies 
Competitive binding studies were performed 
with cell membrane preparations. Therefore, cellular 
monolayer cultures were washed with pre-warmed 
PBS and dissociated in ice-cold PBS with 5 mM 
ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′- 
tetraacetic acid (EGTA) (Carl Roth, Karlsruhe, 
Germany) with the help of a cell scraper. Tumor tissue 
was homogenized with a rotor-stator homogenizer 
(Ultra-Turrax T8, IKA-Werke, Staufen, Germany) in 
ice-cold PBS with 5 mM EGTA. Both, cell and tissue 
homogenates were centrifuged for ten minutes (4 °C, 
200 x g), and supernatants were discarded. Pellets 
were resuspended in 5 mL of membrane isolation 
buffer (5 mM TrisHCl pH 7.6, 5 mM MgCl2, 1 mM 
EGTA, protease inhibitor cocktail cOmplete [Roche 
Applied Science, Penzberg, Germany]) with a glass 
dounce tissue grinder (Wheaton, Millville, USA) and 





further homogenized by moving the pestle up and 
down (approx. 30 times). After centrifugation for 30 
minutes (4 °C und 40.000 x g), the process was 
repeated, before cell and tissue homogenates were 
resuspended in 1 mL membrane isolation buffer, 
aliquoted and stored at -80 °C. For competitive 
binding, 5 µg of isolated membrane in 25 μL binding 
buffer (50 mM HEPES pH 7.4, 5 mM MgCl2, 1 mM 
CaCl2, 0.5% bovine serum albumin [BSA], protease 
inhibitor cocktail cOmplete) were incubated with 
increasing concentrations of non-radioactive peptide 
(2-fold concentrated in 50 µL) and 100,000 cpm of 
[125I]Tyr149-chemerin-9 (125I-chemerin-9) (in 25 μL 
binding buffer). After one hour of incubation at 37 °C, 
the mixture was transferred to 96-well filter plates 
(MultiScreenHTS FB Filter Plate 1.0 µm, Millipore, 
Billerica, USA), unbound peptide was withdrawn by 
suction and the plate was washed four times with 
cold washing buffer (50 mM Tris-HCl pH 7.4, 125 mM 
NaCl, 0.05% BSA). After drying the filter plate, 40 μL 
scintillation cocktail (Ultima Gold F, Perkin Elmer, 
Waltham, USA) per well was added and radioactivity 
was measured by liquid scintillation counting 
(MicroBeta2 Microplate Counter, PerkinElmer, 
Waltham, USA). For saturation binding, binding 
buffer was prepared with varying concentrations of 
labeled peptide from 0 to 5 nM, either with 
(non-specific binding, NSB) or without 5 μM of 
additional unlabeled peptide (total binding, TB). 
Saturation binding was performed to determine the 
maximum number of binding sites Bmax. Therefore, 
non-specific binding was subtracted from total 
binding to obtain specific binding (SB). By non-linear 
regression (one site - total and non-specific, one site - 
specific binding), GraphPad Prism 5.04 was used to 
determine the Bmax value of DU4475 cells in cpm 
which was further used to calculate the number of 
binding sites in fmol per mg membrane protein. 
Radiochemical labeling with gallium-68 (68Ga) 
Radiolabeling experiments were performed on a 
Modular Lab PharmTracer synthesis module (Eckert 
& Ziegler, Berlin, Germany) which allows fully 
automated cassette-based labeling of gallium tracers 
utilizing a pharmaceutical grade 68Ge/68Ga generator 
(GalliaPharm, 1.85 GBq, good manufacturing practice 
[GMP]-certified; Eckert & Ziegler GmbH, Berlin, 
Germany). Cassettes were GMP-certified and sterile. 
They were used without pre-conditioning of the 
cartridges. The gallium generator was eluted with 
aqueous HCl (0.1 M, 7 mL) and the eluate was 
purified on an ion-exchange cartridge followed by 
elution using 1 mL of 0.1 M HCl in acetone. The 
peptide-DOTA conjugate (50 µg from a stock solution 
1 mg/mL in 10% dimethyl sulfoxide [DMSO] in 
water) was mixed with 500 µL 0.1 M HEPES buffer 
(pH 7) and heated for 500 seconds at 95 °C. After the 
reaction, the mixture was passed through a C-18 
cartridge for purification and the tracer was eluted 
from the cartridge with ethanol. In order to control the 
quality of radiolabeling, the radiochemical yield, 
purity, and specific activity for all five peptide-DOTA 
conjugates and each individual labeling experiment 
was determined. Overall, a radiochemical yield of 
82.1% ± 6.7%, a radiochemical purity of 98.1 ± 4.6% 
and a molar activity of 8.6 GBq/µmol ± 2.7 GBq/µmol 
was achieved (Table S1). Before animal injection, the 
activity was equilibrated to neutral pH using 1 M 
sodium hydrogen carbonate. It was further diluted 
with saline to ≤ 10% ethanol.  
Radiochemical labeling with lutetium-177 
(177Lu) 
Radiolabeling of peptide-DOTA conjugates was 
carried out manually using 177Lu from ITG Isotope 
Technologies Garching GmbH (Garching, Germany). 
A total of 50 µL (stock solution of peptide at 1 µg/µL 
in 10% DMSO in water) was added to 200 µL of 
acetate buffer (sodium acetate/acetic acid buffer, 0.4 
M, pH 5.0) and 120 µL of gentisic solution prepared by 
dissolving 50 mg of gentisic acid in 1 mL of acetate 
buffer. The resulting mixture was then added to 35 µL 
of 177Lu (1 GBq in aqueous 0.04 M HCl) and the 
reaction mixture was heated at 96 °C for 30 minutes 
followed by cooling for 10 minutes at room 
temperature. The product was then diluted with 5 mL 
of saline and used directly for animal experiments. 
Radiochemical purity determined by HPLC was 
found to be higher than 99% in all cases, 
radiochemical yield was about 95%, and the product 
had a molar activity of approximately 10 GBq/µmol. 
Non-radioactive labeling with natGa, natLu and 
natY 
Non-radioactive complexes of the 
peptide-DOTA conjugates with native gallium, 
lutetium, and yttrium were synthesized by incubation 
of 3 nmol peptide conjugate dissolved in 30 µL buffer 
(sodium acetate/acetic acid buffer, 0.5 M, pH 5.4) 
using 10-fold molar excess of the metal ion. The 
reaction was carried out for 30 minutes at 95° C and 
followed by HPLC purification on a C18 column. 
PET/MR imaging 
Positron emission tomography (PET) / magnetic 
resonance imaging (MRI) (1 Tesla nanoScan 
PET/MRI, Mediso, Hungary) was performed at the 
Berlin Experimental Radionuclide Imaging Center 
(BERIC), Charité – Universitätsmedizin Berlin. A 
dedicated mouse whole-body coil was used for 





RF-transmission and signal receiving. Mice were 
anesthetized using 1-2% isoflurane/0.5 L/min 
oxygen. Body temperature was maintained at 37 °C 
during the time of imaging by using a heated bed 
aperture. Anatomic whole-body MRI scans were 
acquired using a high-resolution T2-weighted 2D fast 
spin echo sequence (T2 FSE 2D) with the following 
parameters: TR = 8700 ms; TE = 103 ms; slice 
thickness/gap = 1.1 mm/ 0.1 mm; matrix = 256 x 256 
mm; external averages = 5 and number of excitations 
= 2. PET scans in list mode were acquired either for 30 
minutes one and two hours after intravenous injection 
or for 90 minutes of dynamic imaging starting directly 
before injection of 0.15 mL of tracer, corresponding to 
a 68Ga activity of approximately 20 MBq for static 1 
h-images and 2 h-images and 15 MBq for kinetic 
imaging. To determine the effect of unlabeled ligand 
on the tumor uptake, 200 nmol CG34 peptide 
(approximately 50-fold excess) was co-injected. Static 
PET images were reconstructed from the raw data as 
one image (1 x 1800 s) and dynamic PET images were 
reconstructed with the image sequence 9 x 600 s. The 
uptake value (kBq/cm3) in the tumor tissue was 
determined by manual contouring of a volume of 
interest (VOI) of the PET images using PMOD 3.610 
(PMOD Technologies, Zürich, Switzerland). 
Biodistribution studies  
Tumor-bearing mice were injected with 
approximately 10 MBq of 68Ga-labeled DOTA-peptide 
or 1 MBq of 177Lu-labeled DOTA-peptide to the tail 
vein via a catheter. Mice were sacrificed and dissected 
one or two hours after injection. Tumor, blood, 
stomach, pancreas, small intestine, colon, liver, 
spleen, kidney, heart, lung, muscle and femur 
samples were weighed and uptake of radioactivity 
was measured by a gamma counter. To determine the 
effect of unlabeled ligand on the tumor uptake, 200 
nmol CG34 peptide (100-fold excess) was co-injected. 
Statistical analysis 
All statistical analyses were performed using 
GraphPad Prism 5.04. EC50/IC50 values were 
determined by nonlinear sigmoidal curve fitting with 
variable slope setting, and normalized response for 
competitive binding results. Multiple group 
comparisons were done by a two-way ANOVA and 
Bonferroni post hoc test. All presented data are based 
on independent experiments. Normalizations and 
statistics are further defined in each figure legend.  
Data availability 
Numerical data for all experiments (xlsx file) 
have been deposited in an open data repository for 
public access: https://doi.org/10.5281/zenodo. 
3334766 
Results 
Characterization of an endogenously 
CMKLR1-expressing tumor mouse model 
As model for tracer testing, the human breast 
cancer cell line DU4475, which endogenously 
expresses high levels of CMKLR1, and the 
target-negative human lung cancer cell line A549 
were chosen to induce subcutaneous xenograft 
tumors in nude mice. Analysis of ex vivo tumor tissue 
confirmed CMKLR1 expression in DU4475 xenografts 
by immunostaining, whereas A549 tumors showed no 
detectable antigen (Figure 1A). To confirm presence of 
receptor protein in DU4475 cells with an independent 
method, saturation binding studies were performed 
on membrane preparations of cultured cells (Figure 
1B). The assessment of total (TB) and non-specific 
binding (NSB) of 125I-labeled chemerin-9 was used to 
determine the specific binding (SB) of the radioligand 
to CMKLR1 and further to calculate the maximum 
number of binding sites Bmax (27.40 ± 2.97 fmol/mg). 
Competitive binding studies were used for 
comparison of both cell lines in vitro and ex vivo 
(Figure 1C). Receptor binding of 125I-labeled 
chemerin-9 in DU4475 cell membrane preparations (in 
vitro) led to values around 200 cpm (assessment of 
radioactivity by liquid scintillation counting) which 
could be significantly blocked (approx. 80 cpm) by an 
excess of the unlabeled peptide (1 µM). Membranes 
isolated from DU4475 tumors (ex vivo) bound less 
labeled peptide (approx. 115 cpm) but still exhibited 
specific binding, as 1 µM chemerin-9 clearly displaced 
about 50% of the bound activity (60 cpm). In contrast, 
membrane preparations from A549 cells and 
xenograft tumors showed no specific binding.  
Characterization of high-potency, high-affinity 
CMKLR1-targeting peptide-DOTA conjugates 
Chemical design of five tracers for CMKLR1 
targeting involved two peptide analogs (CG34: 
Y-Cha-Hyp-G-Cit-F-a-Tic-S and CG36: Y-Cha-P-G-M- 
Y-A-F-f) of the CMKLR1 ligand chemerin-9 
(Y-F-P-G-Q-F-A-F-S) that were attached to the 
chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10- 
tetraacetic acid (DOTA) via one of four different 
chemical linkers: 4,7,10-trioxatridecan-succinamic 
acid (TTDS), 6-aminohexanoic acid (AHX), 
N-ɛ-capryloyl-lysine (KCap) and 10-aminodecanoic 
acid (ADX) (Figure 2A). Due to their chemical 
composition, both peptide analogs as well as the four 
linkers exhibit distinct characteristics such as different 
length and hydrophobicity. In Figure 2A, these 
conjugate components are depicted in different colors 
(reddish colors indicate more hydrophobic properties 
and greenish colors more hydrophilicity). As a 





measure for their hydrophobicity, LogD7.4 values were 
determined as -1.01 ± 0.39 for DOTA-TTDS-CG34, 
-0.96 ± 0.2 for DOTA-AHX-CG34, 1.29 ± 0.68 for 
DOTA-KCap-CG34, 1.35 ± 0.31 for DOTA-ADX- 
CG34, and 2.27 ± 0.47 for DOTA-AHX-CG36.  
In vitro characterization of the probes was 
realized by activity and radioligand binding studies in 
HEK293a cells stably transfected with CMKLR1. 
Ligand-induced receptor activation as intracellular 
Ca2+ flux was quantified in an intracellular calcium 
mobilization assay (Figure 2B). Concentration- 
response profiles for all five tracers were determined 
and EC50 values were calculated. In comparison to the 
unconjugated peptide analog CG34 (EC50 0.4 nM), the 
TTDS-linked DOTA conjugate of CG34 had a slightly 
higher EC50 value of 1.51 nM. Receptor affinity was 
assessed by competitive radioligand binding studies 
and resulting IC50 values were derived (Figure 2C). 
Furthermore, DOTA conjugates were labeled with 
non-radioactive gallium (natGa) to investigate a 
potential impact of metal ion complexation on 
binding affinity. For DOTA-TTDS-CG34, gallium- 
labeling barely had an effect on receptor binding (IC50 
value approximately 0.6 nM). As the unconjugated 
peptide CG34 exhibited an IC50 of 1.0 nM, conjugation 
with DOTA had even increased its binding affinity. 
Figure 2D summarizes all EC50 and IC50 values of the 
five DOTA peptide conjugates. All CG34 conjugates 
showed EC50 values within the low nanomolar range 
of approx. 0.6 – 1.5 nM, thus, 1.6- to 3.8-fold higher 
values for receptor activation than for the 
unconjugated peptide. However, for receptor binding 
the IC50 values were similar to the value for CG34 or 
even lower (subnanomolar range: approx. 0.3 – 1.0 
nM) and non-radioactive gallium labeling did not 
adversely affect the affinity. Compared to the 
activating potency (EC50 0.9 nM) and binding affinity 
(IC50 0.1 nM) of the unconjugated peptide CG36, the 
DOTA-AHX-CG36 probe exhibited only slightly 
higher values (EC50 1.53 nM, IC50 w/o natGa 0.13 nM 
and w/ natGa 0.13 nM).  
 
 
Figure 1: Characterization of the xenograft tumor model. Breast cancer DU4475 and lung cancer A549 cells were employed to establish a xenograft model with both 
CMKLR1-positive and -negative tumor. (A) Immunostaining of xenograft cryosections revealed CMKLR1 immunostaining (green) in DU4475 ex vivo tissue whereas the A549 
tumor showed no signal. (blue: cell nuclei; bar = 50 µm) (B) Saturation binding studies with increasing concentrations of 125I-labeled chemerin-9 allowed analysis of total (TB), 
non-specific (NSB) and specific binding (SB) to DU4475 cell membranes either without (-) or with (+) blocking excess of 5 µM unlabeled ligand. The Bmax value for DU4475 cells 
(27.40 fmol/mg) was then determined by non-linear regression and one site - specific binding analysis. Data were obtained from three independent experiments, values are 
indicated as means ± SEM. (C) Competitive radioligand binding studies using 125I-labeled chemerin-9 showed specific binding to DU4475 cell membranes (in vitro) and xenograft 
tumor membranes (ex vivo), which could be blocked by 1 µM unlabeled ligand. In contrast, A549 cells as well as A549 xenografts showed no specific binding. Data were obtained 
from at least three independent experiments and values are indicated as means ± SEM. (**** P < 0.0001, * P < 0.05) 






Figure 2: Characterization of DOTA peptide conjugates regarding their functionality and affinity. (A) The chelating agent 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was conjugated to the N-terminus of one of the two optimized chemerin peptide analogs, CG34 and CG36, by 
one of the four chemical linkers. (B) By functional Ca2+ mobilization assay, the concentration-response curve for the TTDS-linked CG34 conjugate could be determined and the 
resulting EC50 value (1.51 nM) confirmed its high receptor-activating potency. Response data are presented as mean ± SEM of three independent experiments. (C) Ligand affinity 
to the receptor was assessed by competitive radioligand binding experiments using 125I-chemerin-9 as radioligand. Displacement binding curves revealed similar IC50 values of the 
labeled (with natGa) and unlabeled (without natGa) DOTA conjugate indicating high affinity. Data are shown as mean ± SEM of three independent experiments normalized to 
non-competed radioligand binding. (D) To assess how the conjugation affects the ligand characteristics, functional and affinity data were obtained accordingly for all five chemerin 
conjugates (summarized as EC50/IC50 values). The Ca2+ and binding assays were performed with HEK293a cells stably expressing huCMKLR1 and Gα16. All EC50/IC50 values were 
obtained from three independent experiments and are indicated as means ± SD. (green colors indicate more hydrophilic, red more hydrophobic properties of peptides and 
linker) 
 
In vivo PET/MR imaging and biodistribution 
studies demonstrate specific tracer uptake in 
CMKLR1-expressing tumors 
An initial PET study was performed to estimate 
the in vivo behavior of the five tracer conjugates after 
68Ga-labeling. Tumor-bearing mice received an 
intravenous injection of approximately 20 MBq 
radiotracer and were imaged for 30 minutes starting 
one hour post-injection in the PET/MRI scanner. 
Figure 3 shows in vivo PET images of the five tracers, 
depicted with hydrophobicity increasing from left to 
right. The most hydrophilic tracer [68Ga]Ga-DOTA- 
TTDS-CG34 accumulated mainly in the kidneys 
(Figure 3A, yellow arrow) with no clear DU4475 
tumor uptake (right shoulder) compared to the 
general background. With [68Ga]Ga-DOTA-AHX- 
CG34, tumor-to-background signal was found to be 
higher (Figure 3B, white arrow) and accompanied by 
less kidney uptake. The tracer uptake within the 





target-positive tumor on the right shoulder was even 
more enhanced with KCap as linker (Figure 3C, white 
arrow). The most hydrophobic CG34 tracer, with ADX 
as a linker, also led to specific tumor uptake (Figure 
3D, white arrow), but also high kidney (yellow arrow) 
and apparent liver uptake (red arrow). For the tracer 
[68Ga]Ga-DOTA-AHX-CG36, kidney and liver signals 
were high but almost no tumor uptake could be 
detected (Figure 3E). Based on these initial in vivo 
findings, the three most promising tracers 
[68Ga]Ga-DOTA-AHX-CG34, [68Ga]Ga-DOTA-KCap- 
CG34 and [68Ga]Ga-DOTA-ADX-CG34 were further 
analyzed. In addition to PET/MRI scans, ex vivo 
biodistribution studies were performed.  
In vivo hybrid imaging with [68Ga]Ga- 
DOTA-KCap-CG34 and [68Ga]Ga-DOTA-ADX-CG34 
using the PET/MRI scanner enabled not only 
functional PET analysis of the tracers but also allowed 
to gain anatomical insights into the tumor tissue and 
volume by high-resolution T2-weighted MR imaging 
(upper panels, Figure 4). As seen in the T2-weigthed 
images, both tumors (A549 on the left and DU4475 on 
the right shoulder) were of comparable size, tissue 
characteristics and vascularization. The KCap-linked 
radiotracer apparently accumulated in the DU4475 
tumor and in kidneys one hour post-injection with 
decreasing PET signals after two hours. In contrast, no 
clear A549 tumor signal could be detected (upper 
panel, Figure 4A). In addition to in vivo imaging, 
tumor-bearing mice were injected with approximately 
10 MBq of radiotracer and sacrificed after one and two 
hours, respectively. By ex vivo measurement, tissue 
radioactivity was calculated as percentage of injected 
activity per gram tissue (% IA/g). After one hour, 
[68Ga]Ga-DOTA-KCap-CG34 led to a DU4475 tumor 
uptake of about 3.3% IA/g and was 1.4-fold less in the 
A549 tumor with approx. 2.3% IA/g. Furthermore, 
higher values were measured for spleen (approx. 4.9% 
IA/g) and, due to the predominant renal excretion of 
peptides, for kidneys (approx. 5.8% IA/g). The 
DU4475 uptake decreased to approx. 2.9% IA/g, 
whereas the kidney signal increased up to approx. 
6.5% IA/g two hours post-injection (lower panel, 
Figure 4A). For [68Ga]Ga-DOTA-ADX-CG34, the PET 
signal in DU4475 tumor and kidneys was 
comparatively stronger one and two hours 
post-injection than the uptake of 
[68Ga]Ga-DOTA-KCap-CG34 and there was also an 
additional distinct liver uptake of the radiotracer 
(upper panel, Figure 4B). These higher organ uptakes 
were confirmed by biodistribution data (lower panel, 
Figure 4B). In addition to overall higher values one 
hour after injection, liver (approx. 14.2% IA/g), 
kidney (10.3% IA/g) and spleen (7.8% IA/g) uptakes 
were the most profound off-target effects. However, 
with approx. 6.2% IA/g for CMKLR1-positive 
DU4475 tumors and approx. 2.7% IA/g for 
target-negative A549 tumors, PET results and tracer 
specificity could be confirmed. After two hours, 
DU4475 uptake declined by 1.5-fold to approx. 4.2% 
IA/g and a distinct liver uptake (approx. 12.5% IA/g) 
persisted. Kinetic measurements of tracer 
concentration in tumors, kidneys and liver 
demonstrated a delayed kidney peak for 
 
Figure 3: Comparison of tracer biodistribution by PET imaging. Representative static PET images were acquired for 30 minutes one hour post-injection of the five 
68Ga-labeled DOTA conjugates in a DU4475/A549 tumor model and revealed a differential distribution. Approximately 20 MBq of each tracer were injected intravenously. (A) 
Predominant renal excretion of the hydrophilic tracer [68Ga]Ga-DOTA-TTDS-CG34 is indicated by a pronounced kidney signal (yellow arrow). (B-C) The more hydrophobic 
linkers AHX and KCap led to less kidney signal, but more distinct DU4475 uptake (white arrows). (D) Beside the kidney uptake, [68Ga]Ga-DOTA-ADX-CG34 induced an 
increased liver signal (red arrow). (E) [68Ga]Ga-DOTA-AHX-CG36 showed a comparable kidney and liver uptake, but less accumulation in the DU4475 tumor. 





[68Ga]Ga-DOTA-KCap-CG34, with rapid washout 
from kidneys for both [68Ga]Ga-DOTA-AHX-CG34 
and [68Ga]Ga-DOTA-ADX-CG34 (Figure S2). While 
the other two tracers showed a small decline in the 
DU4475 tumor, [68Ga]Ga-DOTA-ADX-CG34 appeared 
to gain in tumor activity until 90 minutes p.i. 
Receptor blocking studies verify tracer 
specificity  
For further investigation of CMKLR1 specificity 
of the radiotracers, blocking experiments were carried 
out. To examine whether tracer binding to the tissues 
could be displaced, PET/MR imaging was performed 
twice with the same animal, once with and once 
without an excess of unlabeled peptide. In parallel, 
biodistribution experiments under blocking 
conditions (excess of unlabeled peptide) were 
performed to confirm PET results independently in a 
quantitative manner.  
Figure 5 shows representative results of in vivo 
receptor blocking experiments with [68Ga]Ga-DOTA- 
AHX-CG34. PET/MR imaging without excess of the 
unconjugated and unlabeled peptide CG34 showed 
DU4475 tumor and kidney signals one hour 
post-injection (Figure 5A). However, co-injection of 
200 nmol CG34 (50-fold excess) led to a complete loss 
of tumor uptake and a highly enhanced kidney signal 
(Figure 5B). The tracer biodistribution one hour after 
 
Figure 4: PET/MR imaging and biodistribution study with CMKLR1-targeted, chemerin-based tracers [68Ga]Ga-DOTA-KCap-CG34 and 
[68Ga]Ga-DOTA-ADX-CG34. Representative static PET images were acquired for 30 minutes one and two hours post-injection (p.i.) of 20 MBq 68Ga-labeled conjugate in 
DU4475 (target-positive) and A549 (negative) tumor model (upper panel). For quantitative analysis of tracer biodistribution, 10 MBq of the tracer was injected intravenously and 
tissue was analyzed ex vivo one or two hours p.i. Values for tracer uptake are indicated as percent injected activity per gram tissue (% IA/g) (lower panel). (A) The T2-weighted 
MRI image clearly shows both tumors on the animal´s shoulders. The PET images reveal [68Ga]Ga-DOTA-KCap-CG34 uptake in DU4475 after one hour, which decreased two 
hours p.i. The A549 tumor accumulated much less activity. Beside tumor uptake, the tracer accumulated in the kidneys after one hour. The quantitative analysis of biodistribution 
one hour p.i indicates more tracer uptake in DU4475 than in A549. Predominant renal excretion is represented by a noticeable kidney value (3 ≤ n ≤ 15; mean ± SEM). (B) 
Injection of [68Ga]Ga-DOTA-ADX-CG34 resulted in strong DU4475 and low A549 uptake. In addition, tracer uptake was detected in kidneys and liver. Quantitative analysis of 
tracer biodistribution after one hour shows a high uptake in DU4475, and less in A549 tumors. Furthermore, the more hydrophobic tracer accumulated in the kidneys, liver and 
spleen and led to an overall stronger and longer organ accumulation (5 ≤ n ≤ 16; mean ± SEM). (n.d. = not determined) 





injection without competing CG34 clearly 
demonstrated the distinct DU4475 tumor uptake 
(approx. 5.1% IA/g) and the high kidney (approx. 
6.5% IA/g) and spleen (approx. 6.3% IA/g) values 
(Figure 5C). CMKLR1 blocking with an excess of 
CG34 led to an overall low tissue and organ 
radioactivity except for strong kidney uptake (8.6% 
IA/g) and excretion into the urinary bladder. The 
tracer uptake within DU4475 tumors could be blocked 
by a factor of 6.4 to approximately 0.8% IA/g (Figure 
5D).  
A summary of all biodistribution data including 
calculated tissue radioactivity ratios for the three most 
promising tracers [68Ga]Ga-DOTA-AHX-CG34, 
[68Ga]Ga-DOTA-KCap-CG34 and [68Ga]Ga-DOTA- 
ADX-CG34 is presented in Table 1. Use of these 
CMKLR1 tracers resulted in distinct target-specific 
DU4475 tumor uptake with 5.1% IA/g 
([68Ga]Ga-DOTA-AHX-CG34), 3.3% IA/g 
([68Ga]Ga-DOTA-KCap-CG34) and 6.2% IA/g 
([68Ga]Ga-DOTA-ADX-CG34). All three of them 
showed favorable tumor-to-kidneys ratios with 0.9, 
0.7 and 0.8. CMKLR1 specificity could be proven by 
1.7-fold (5.1 vs. 3.0% IA/g), 1.4-fold (3.3 vs. 2.3% 
IA/g) and 2.3-fold (6.2 vs. 2.7% IA/g) higher uptake 
in CMKLR1-positive DU4475 tumors than in 
target-negative A549 tumors one hour post-injection. 
In addition, receptor blocking by co-injection of an 
excess of unlabeled chemerin peptide diminished 
specific tracer binding by 6.4-fold (5.1 vs. 0.8% IA/g), 
5.5-fold (3.3 vs. 0.6% IA/g) and 3.4-fold (6.2 vs. 1.8% 
IA/g). The most stable and durable tumor uptake was 
achieved by [68Ga]Ga-DOTA-AHX-CG34 with 4.9% 
IA/g (approx. 96% of the 1 h-value) after two hours, 
whereas uptake of the KCap-linked (approx. 88%) and 
ADX-linked (approx. 68%) tracers declined faster 
within two hours after injection. The highest overall 
non-tumor uptake values were seen with 
[68Ga]Ga-DOTA-ADX-CG34, with considerable liver 
(14.2% IA/g) and kidney (10.3% IA/g) uptake and 




Figure 5: PET/MR imaging and biodistribution study along with a blocking experiment. Representative static PET images were acquired for 30 minutes one and two 
hours p.i. of 68Ga-labeled DOTA-AHX-CG34 conjugate (A) without and (B) with coinjected 50-fold excess of unlabeled peptide CG34 (200 nmol) in the same animal. 20 MBq 
of the tracer were injected intravenously. PET images show a strong DU4475 uptake, which could be completely displaced with excess of non-labeled peptide. Quantitative 
analysis of tracer biodistribution (10 MBq) one hour p.i. (C) without and (D) with receptor blocking confirmed the specific tracer uptake in the DU4475 tumor. (6 ≤ n ≤ 13; mean 
± SEM) 





Table 1: Biodistribution data and tissue radioactivity ratios of 68Ga-labeled chemerin tracers in the DU4475/A549 
xenograft model. Data are presented as mean ± SEM (2 ≤ n ≤ 16) % IA/g of tissue or as a ratio. Blocking studies were performed in the 
presence of 200 nmol of CG34. (n.d. = not determined) 
  [68Ga]Ga-DOTA-AHX-CG34  [68Ga]Ga-DOTA-KCap-CG34  [68Ga]Ga-DOTA-ADX-CG34 
organ 1 h 1 h-blocked 2 h  1 h 1 h-blocked 2 h  1 h 1 h-blocked 2 h 
DU4475 5.1 ± 0.5 0.8 ± 0.1 4.9 ± 0.8  3.3 ± 0.2 0.6 ± 0.1 2.9 ± 0.5  6.2 ± 0.5 1.8 ± 0.1 4.2 ± 1.0 
A549 3.0 ± 0.3 1.1 ± 0.2 1.4 ± 0.1  2.3 ± 0.4 0.6 ± 0.1  n.d.   2.7 ± 0.4 1.6 ± 0.2  n.d.  
small intestine 2.1 ± 0.2 0.4 ± 0.0 2.0 ± 0.4  2.3 ± 0.1 0.3 ± 0.1 1.9 ± 0.3  3.8 ± 0.2 1.4 ± 0.2 4.4 ± 2.0 
colon 2.7 ± 0.3 0.5 ± 0.0 2.6 ± 0.7  2.4 ± 0.2 0.3 ± 0.0 1.7 ± 0.2  3.2 ± 0.3 1.2 ± 0.1 2.3 ± 0.3 
liver 2.4 ± 0.3 0.6 ± 0.0 2.4 ± 0.4  2.2 ± 0.1 0.3 ± 0.0 1.8 ± 0.2  14.2 ± 1.1 10.4 ± 0.9 12.5 ± 1.1 
spleen 6.3 ± 0.8 0.8 ± 0.1 5.0 ± 0.5  4.9 ± 0.5 0.5 ± 0.1 4.0 ± 0.6  7.8 ± 0.6 2.3 ± 0.4 5.4 ± 1.0 
kidney 6.5 ± 0.9 8.6 ± 1.4 6.6 ± 1.1  5.8 ± 0.9 5.2 ± 0.9 6.5 ± 1.3  10.3 ± 1.7 14.5 ± 3.9 5.5 ± 1.6 
heart 1.2 ± 0.1 0.4 ± 0.0 1.1 ± 0.3  1.1 ± 0.1 0.2 ± 0.0 0.8 ± 0.1  2.2 ± 0.2 1.4 ± 0.1 1.2 ± 0.1 
blood 1.2 ± 0.4 0.8 ± 0.1 0.4 ± 0.1  0.6 ± 0.1 0.5 ± 0.1 0.2 ± 0.0  2.8 ± 0.7 3.2 ± 0.3 0.8 ± 0.1 
lung 4.2 ± 0.5 1.0 ± 0.1 2.8 ± 0.3  1.7 ± 0.1 0.5 ± 0.1 1.2 ± 0.1  7.1 ± 0.7 3.4 ± 0.2 3.9 ± 0.4 
muscle 0.7 ± 0.1 0.2 ± 0.0 0.5 ± 0.1  0.6 ± 0.1 0.2 ± 0.1 0.4 ± 0.1  1.1 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 
femur 0.8 ± 0.1 0.2 ± 0.0 0.7 ± 0.1  0.6 ± 0.1 0.2 ± 0.1 0.5 ± 0.1  1.3 ± 0.2 0.7 ± 0.1 0.7 ± 0.1 
stomach 1.7 ± 0.2 0.4 ± 0.0 1.3 ± 0.1  1.4 ± 0.1 0.3 ± 0.1 1.1 ± 0.2  2.2 ± 0.2 1.1 ± 0.1 1.5 ± 0.2 
pancreas 1.0 ± 0.1 0.3 ± 0.0 0.8 ± 0.1  0.9 ± 0.1 0.2 ± 0.0 0.7 ± 0.1  1.7 ± 0.2 0.8 ± 0.1 1.1 ± 0.1 
tumor-to-blood 5.9 ± 0.7 1.0 ± 0.1 13.3 ± 3.0  5.6 ± 0.5 1.3 ± 0.3 18.2 ± 3.4  3.0 ± 0.3 0.6 ± 0.1 5.7 ± 1.1 
tumor-to-liver 2.3 ± 0.2 1.2 ± 0.0 2.2 ± 0.5  1.6 ± 0.1 1.8 ± 0.3 1.8 ± 0.4  0.4 ± 0.0 0.2 ± 0.0 0.3 ± 0.1 
tumor-to-kidney 0.9 ± 0.1 0.1 ± 0.0 0.7 ± 0.1  0.7 ± 0.1 0.1 ± 0.0 0.6 ± 0.1  0.8 ± 0.1 0.2 ± 0.0 0.8 ± 0.2 
tumor-to-pancreas 5.6 ± 0.7 2.9 ± 0.2 6.2 ± 1.3  3.7 ± 0.3 3.7 ± 0.5 4.3 ± 0.9  3.9 ± 0.3 2.3 ± 0.2 3.9 ± 0.7 
tumor-to-muscle 8.5 ± 1.0 4.4 ± 0.3 11.4 ± 2.4  6.6 ± 0.7 4.3 ± 0.9 7.2 ± 1.2  6.3 ± 0.5 3.3 ± 0.3 7.2 ± 1.2 
 
Lutetium-labeling of chemerin tracers 
maintained high receptor affinity and target 
recognition in CMKLR1 tumor model 
For further evaluation of their theranostics 
potential, the probes were labeled with 
therapeutically relevant metal ions. Thereby, the 
impact of modified chelation on receptor affinity was 
assessed. DOTA labeling with native non-radioactive 
lutetium and yttrium (natLu and natY) yielded 
high-affinity peptide conjugates with IC50 values 
between 0.8 and 2.6 nM (Figure 6A and B) as 
compared to the gallium-labeled tracers (IC50 values 
between 0.3 and 0.7 nM; Figure 2D). In order to 
prepare for therapeutic use, 177Lu-labeled tracer 
DOTA-AHX-CG34 was used for an initial 
biodistribution study (Figure 6C). The overall tissue 
activity distribution one hour p.i. was comparable to 
the 68Ga-labeled tracer (Figure 5C) with 1.4-fold 
higher uptake in DU4475 (3.3% IA/g) than A549 (2.3% 
IA/g) and apparent values of spleen (5.8% IA/g), 
kidneys (4.7% IA/g) and lung (5.6% IA/g). After 24 
hours, most of the tissue activity diminished with 
only low values left for spleen (1.7% IA/g) and 
kidneys (1.0% IA/g). However, the uptake of 
target-positive DU4475 tumor was 2.1% IA/g 
(approx. 64% of the 1 h-value) and with this 5.3-fold 
higher than the A549 value (0.4% IA/g) 24 hours p.i. 
Discussion and Conclusions 
The purpose of this study was to evaluate a 
family of five novel CMKLR1 tracers for their capacity 
to generate target-specific signals in a breast cancer 
xenograft mouse model. To the best of our 
knowledge, this is the first report of CMKLR1 in vivo 
imaging. Although known for its role in inflammation 
and metabolic regulation for many years, CMKLR1 
and its chemokine-like ligand chemerin were only 
recently recognized as modulators of tumor 
proliferation and expansion. Other labs have reported 
overexpression and functional involvement of 
CMKLR1 in esophageal squamous cell carcinoma, 
hepatocellular carcinoma, neuroblastoma and gastric 
cancer [19-22]. Here, we introduce two peptide 
analogs of chemerin for use in receptor-mediated 
tumor targeting. These peptide analogs are based on 
chemerin-9, which has full agonistic activity towards 
the receptor CMKLR1 and corresponds to the 
C-terminal nine amino acids of processed chemerin 
[14]. In a previous study, we have shown the potential 
to generate stable and potent chemerin-9 analogs by 
the introduction of D-amino acids via an evolutionary 
algorithm [24]. The resulting peptide analogs showed 
improved properties concerning receptor activation, 
binding affinity and metabolic stability. In this study, 
we have made use of such analogs as components of 
chelator conjugates to do PET/MR imaging in a breast 
cancer xenograft mouse model. 
The suitability of the animal model with 
CMKLR1-positive DU4475 and CMKLR1-negative 
A549 xenograft tumors was confirmed by 
immunofluorescence staining and radioligand 
binding studies. As expression of proteins in cells may 
change upon transfer from the culture dish monolayer 
to three-dimensional subcutaneous xenograft in mice, 
we also investigated CMKLR1 expression in tumor 
tissue. Thereby, overexpression as well as ligand 
binding were established for DU4475 tumors while 
A549 tumors were confirmed as a negative control.  






Figure 6: Binding affinity and biodistribution of lutetium- and yttrium-labeled chemerin tracers. (A) Ligand affinity to CMKLR1 was assessed by competitive 
radioligand binding experiments using 125I-chemerin-9 as radioligand. Displacement binding curves revealed similar IC50 values of the natLu-labeled and natY-labeled 
DOTA-AHX-CG34 conjugate indicating a maintained high affinity around 1 nM. Data are shown as mean ± SEM of two independent experiments. (B) Binding assays were 
performed accordingly for the three CG34 conjugates with AHX, KCap and ADX linker (summarized as IC50 values). All IC50 values were obtained from two independent 
experiments and are indicated as means ± SD. (C) For quantitative analysis of tracer biodistribution, approx. 1 MBq of the 177Lu-labeled tracer DOTA-AHX-CG34 was injected 
intravenously and tissue was analyzed ex vivo one or 24 hours p.i. Values for tracer uptake are indicated as percent injected activity per gram tissue (% IA/g). Biodistribution after 
one hour shows an apparent uptake in DU4475 (3.3% IA/g), and less in A549 tumors (2.3% IA/g). Furthermore, the tracer accumulated in the kidneys, spleen and lung and led to 
a biodistribution comparable to the 68Ga-labeled tracer. After 24 hours, the highest uptake was detectable in DU4475 tumors with approx. 2.1% IA/g (2 ≤ n ≤ 4; mean ± SEM). 
 
In the design of our tracers, we followed the 
hypothesis that tumor uptake and biodistribution 
may depend on a balance of hydrophobic and 
hydrophilic properties within the molecule. 
Therefore, we chose not only to make use of a more 
hydrophilic and a more hydrophobic CMKLR1 
peptide ligand analog, but also to take advantage of 
different linkers to introduce a varying degree of 
hydrophobicity into the conjugates. As the chelator 
DOTA with its four carboxylic groups confers rather 
strong hydrophilic features, we chose to compensate 
this with mainly hydrophobic linker moieties: 
6-aminohexanoic acid (AHX), N-ɛ-capryloyl-lysine 
(KCap) and 10-aminodecanoic acid (ADX). Only one 
linker displayed rather hydrophilic properties: the 
polyethylene glycol (PEG)-like 4,7,10-trioxatridecan- 
succinamic acid (TTDS) (Figure 2A). Unexpectedly, 
the LogD7.4 values of AHX and TTDS compounds 
were rather similar (-0.96 and -1.01, respectively). The 
ADX and KCap conjugates also showed comparable 
hydrophobicity (LogD7.4 approximately 1.3), while the 
only CG36 conjugate was considerably more 
hydrophobic (LogD7.4 2.27). This set of five DOTA 
peptide conjugates was tested in vitro prior to the 
animal study. Of note, all these tracers proved to be of 
high affinity and functional activity, with IC50 and 
EC50 values being below 2 nM (Figure 2D). Affinity 
also did not change significantly upon complexation 
of DOTA with natural non-radioactive gallium 
(natGa), and if so, IC50 values even improved. This was 
in many ways unexpected as we and others had often 
experienced an impairment of the binding and 
activating capacity of ligands upon conjugation with a 
linker and a reporter such as a chelator or dye 
molecule [25-28]. Likewise, the affinity of such a 
conjugate may be affected by the coordination of a 
radiometal ion [29]. The structural requirements of 
chemerin analogs binding to CMKLR1 obviously 
allow for a broad variety of additions to the 
N-terminus of the nonameric peptide. Even though 
the two most potent conjugates were the ones with the 
shortest linkers (AHX and ADX), differences were 
small and a significant systematic influence of linker 
hydrophobicity or length on affinity or activity was 
not observed.  





The initial PET studies using all five tracers 
revealed a clear difference regarding tumor uptake 
and biodistribution: the most hydrophilic conjugate 
([68Ga]Ga-DOTA-TTDS-CG34) and the most 
hydrophobic conjugate ([68Ga]Ga-DOTA-AHX-CG36) 
both showed lower tumor and higher kidney uptake 
than the three conjugates with balanced 
hydrophilicity in the molecule (Figure 3). This was 
also confirmed by results from biodistribution 
experiments: for both tracers, there was no clear 
difference in uptake between target-positive and 
target-negative tumor (Figure S1 and Table S2). These 
results may indicate the validity of our hypothesis 
that sufficient and specific tumor uptake may be 
achieved best using a conjugate with moderate, 
balanced hydrophilicity. Both highly hydrophobic 
and strongly hydrophilic tracers may primarily yield 
unspecific uptake in kidney and liver. Liver uptake is 
notable for the tracer [68Ga]Ga-DOTA-ADX-CG34 
with 14.2% IA/g at one hour, 12.5% IA/g at two 
hours. In addition, [68Ga]Ga-DOTA-AHX-CG36 
shows 6.4% and 4.9% liver uptake (IA/g), 
respectively. The other three probes do not 
accumulate in the liver more than 2.6% IA/g at any 
time. High liver uptake may yield a significant 
radiation dose delivered to the healthy organ, limiting 
its potential therapeutic utility. Moreover, imaging of 
metastatic lesions in the liver might be constricted. 
By peptide optimization and conjugation, we 
were able to obtain a family of five high-potency, 
high-affinity molecular probes for further in vivo 
application as radiotracers. In addition to PET/MRI 
scans one and two hours post-injection, ex vivo 
biodistribution studies were performed to assess 
quantitative values for tissue uptake. Utilizing a 
breast-cancer xenograft mouse model, PET/MRI and 
concomitant biodistribution studies revealed the 
specificity of our chemerin-based radiotracers by 
distinct PET signals and uptake values of 
CMKLR1-positive DU4475 tumors compared to no 
PET visibility and low tumor radioactivity values of 
target-negative A549 tumors. The moderate tracer 
uptake seen in the latter is probably due to unspecific 
mechanisms such as non-selective transporters, 
hydrophobic interaction or blood pool activity. 
Kidney uptake often limits therapeutic use of tracers. 
For the three best tracers described in this study, renal 
uptake was between 5.8 to 10.3% IA/g, resulting in 
favorable tumor-to-kidney ratios of 0.7 to 0.9 at one 
hour post injection.  
Further evidence for the specificity of the tracer 
was obtained in a blocking experiment with an excess 
of non-labeled peptide (Figure 5). As obvious from 
both PET/MR images as well as biodistribution data, 
this excess strongly reduced uptake of the tracer 
[68Ga]Ga-DOTA-AHX-CG34 in CMKLR1-positive 
DU4475 tumors, indicating displacement of the 
radioligand from its receptor. The lower uptake 
observed in other organs probably also corresponds 
to tracer displacement from chemerin receptors 
known to be expressed there (e.g. lung, spleen) [11, 
30]. The dynamic PET scan of [68Ga]Ga-DOTA- 
AHX-CG34 showed faster background/off-target 
clearance as well as fast and stable accumulation at 
tumor sites. Higher hydrophobicity of KCap and ADX 
may have contributed to delayed and prolonged 
kidney uptake, possibly due to plasma protein 
binding or metabolization in the liver (Figure S2). 
While a tumor uptake of 3 to 6% represents a 
promising targeting result for these first CMKLR1 
tracers, several options for an improvement remain. 
One current limitation, especially for an application in 
peptide receptor radionuclide therapy (PRRT), is the 
fast elimination of the signal from the target-positive 
tumor. According to biodistribution data, the signal 
decrease between one hour and two hours in DU4475 
tumors was about 5 to 30%. With the tracer 
[177Lu]Lu-DOTA-AHX-CG34, a 1.4-fold higher uptake 
in DU4475 (3.3% IA/g) than A549 (2.3% IA/g) was 
observed. The decrease from one to 24 hours p.i. here 
was even higher (approximately 36%) than for the 
corresponding 68Ga compound. Before a therapeutic 
application can be considered, uptake and persistence 
in the tumor should be improved, i.e. by modulating 
the molar activity of the tracer. Although the 
underlying peptide analogs have been selected for 
their improved stability in in vitro protease 
degradation assays, a degradation due to proteolytic 
activity in circulation and target tissue may play a 
role. Similarly, fast excretion via the renal pathway, as 
well as hepatic degradation (e.g. 
[68Ga]Ga-DOTA-ADX-CG34) may create unfavorable 
distribution kinetics. The precise causes for this rapid 
decrease in tumor signal will have to be determined in 
subsequent studies. Biochemical isolation and 
analysis of tracer metabolites from the animal’s 
circulation may provide a means of clarifying the 
underlying mechanism. 
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